The not so nice NICE has done it again, refusing to cover an effective life-extending drug called Lapatinib, approved by the FDA since 2007 (meaning it isn’t experimental), that can extend the lives of late stage breast cancer patients. And in this cruelty, is seen vividly the Obamacare future if we don’t revoke the NICE-like powers over both private and public insurance granted under the new law. From the story:
LONDON, June 9, 2010-Today the National Institute for Health and Clinical Excellence (NICE) issued its Final Appraisal Determination (FAD) advising against NHS funding for oral Tyverb (lapatinib) in combination with Xeloda® (capecitabine) for the treatment of an aggressive form of advanced breast cancer (ErbB2/HER 2 – positive)…There are no other licensed ErbB2 targeted treatment options available to suppress the advanced disease once it has stopped responding to trastuzumab. Tyverb has demonstrated that it may increase survival by around three months, compared with capecitabine alone…The decision from NICE sets the UK apart from much of the rest of Europe. Lapatinib is currently funded in 18 countries including Czech Republic, Iceland, Ireland, Slovakia and Slovenia where it is actually more expensive than in the UK.
Dr Alison Jones, Medical Oncologist at the University College London Hospital and the Royal Free Hospital commented: “NICE’s decision places the UK in contrast to other European countries, which allow access to this much needed treatment option for their patients. This is an effective oral treatment that can offer significant extra time and is the only option for some women. Meeting colleagues this week during ASCO, one of the world’s leading cancer meetings, and hearing how treatments such as lapatinib are internationally the standard of care at this stage of the disease, highlights the gulf developing between provision of cancer drugs in the UK and other comparable countries.” The Royal College of Physicians has also expressed disappointment at the ruling for patients, describing lapatinib as an ‘effective therapy that is very likely to make a difference to their overall quality of life, contribution to society and survival.’
Not according to the bureaucrats’ callous mathematical calculations and discriminatory quality of life judmentalism charts.
This is the cost of the kind of centralized control that now threatens quality of care in the USA. We cannot allow rationing to become part of the American health care system. Revoke. Reform. Replace. Defund.
Dear Reader,
Can I be direct with you?
War abroad. Socialists on the rise. AI upending human life. Endless uproar online. The modern attention economy doesn’t want readers — it wants users enslaved to the tyranny of the present.
First Things is the antidote: literary excellence, timeless truths, and a fixed point of reference in a culture that has lost its bearings.
But we can’t do it without readers like you.
Our goal: Raise $150,000 by November 1 to sustain First Things in the year ahead.
Your gift anchors readers in the permanent things.
Make your Fall Campaign gift now using the button below.
If you have any questions or would like more information, please contact Giovanni Del Piero, Director of the Editor’s Circle, at gdelpiero@firstthings.com or 212-627-1985.
YOU MIGHT ALSO LIKE
The Church in the Age of Therapy
In 1966, Philip Rieff wrote in The Triumph of the Therapeutic that “Religious man was born to…
Canada’s Deadliest Blind Spot
On September 20, the Daily Mail ran a story with the provocative headline, “Our 83-year-old Christian grandmother…
The Faithful Joy of Dolly Parton and Fulton Sheen
Dolly Parton and Fulton Sheen seem to have had little in common. She favored rhinestones; he wore…
